KalVista Pharmaceuticals (KALV) Upgraded to Buy: What Does It Mean for the Stock?
KalVista Pharmaceuticals (KALV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
KalVista Pharmaceuticals: Ekterly's Launch Momentum Keeps The Bull Case Alive
KalVista Pharmaceuticals is now a commercial rare-disease play with Ekterly established as the first oral on-demand HAE therapy across seven approved markets. I think Ekterly's convenience versus injectables supports future adoption. Repeat refills have also been a favorable tailwind. Looking ahead, Ekterly's potential pediatric expansion into ages 2 to 11 could add meaningful upside.
KalVista Pharmaceuticals, Inc. (KALV) 8 Months 2025 Earnings Call Transcript
KalVista Pharmaceuticals, Inc. (KALV) 8 Months 2025 Earnings Call Transcript
Wall Street Analysts Think KalVista Pharmaceuticals (KALV) Could Surge 117.1%: Read This Before Placing a Bet
The consensus price target hints at an 117.1% upside potential for KalVista Pharmaceuticals (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion
KalVista Pharmaceuticals retains a 'Strong Buy' rating, driven by EKTERLY's global launch and robust initial sales momentum. Company achieved $35M in Q4 2025 and $49M in full-year 2025 unaudited EKTERLY revenues, with demand in Germany matching the U.S. launch trajectory. Key upside catalyst is the KONFIDENT-KID phase 3 trial, targeting label expansion for pediatric HAE patients ages 2–11, with NDA filing expected Q3 2026.
Wall Street Analysts Believe KalVista Pharmaceuticals (KALV) Could Rally 116.4%: Here's is How to Trade
The consensus price target hints at an 116.4% upside potential for KalVista Pharmaceuticals (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does KalVista Pharmaceuticals (KALV) Have the Potential to Rally 117.98% as Wall Street Analysts Expect?
The mean of analysts' price targets for KalVista Pharmaceuticals (KALV) points to an 118% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
KalVista Pharmaceuticals, Inc. (KALV) Presents at Jefferies London Healthcare Conference 2025 Transcript
KalVista Pharmaceuticals, Inc. ( KALV ) Jefferies London Healthcare Conference 2025 November 19, 2025 8:30 AM EST Company Participants Benjamin Palleiko - CEO & Director Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Presentation Maurice Raycroft Jefferies LLC, Research Division Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies.
KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Tops Revenue Estimates
KalVista Pharmaceuticals, Inc. (KALV) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $0.96. This compares to a loss of $0.91 per share a year ago.
KalVista Pharmaceuticals, Inc. (KALV) Q1 2026 Earnings Call Transcript
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV ) Q1 2026 Earnings Call September 11, 2025 8:30 AM EDT Company Participants Ryan Baker - Head of Investor Relations Benjamin Palleiko - CEO & Director Nicole Sweeny - Chief Commercial Officer Brian Piekos - Chief Financial Officer Paul Audhya - Chief Medical Officer Conference Call Participants Stacy Ku - TD Cowen, Research Division Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Tazeen Ahmad - BofA Securities, Research Division Maurice Raycroft - Jefferies LLC, Research Division Will Soghikian - Leerink Partners LLC, Research Division Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Serge Belanger - Needham & Company, LLC, Research Division Debanjana Chatterjee - JonesTrading Institutional Services, LLC, Research Division Catherine Okoukoni - Citizens JMP Securities, LLC, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. Welcome to KalVista Pharmaceuticals operational update and First Fiscal Quarter Financial Results.
KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates
KalVista Pharmaceuticals, Inc. (KALV) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to a loss of $0.87 per share a year ago.
KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?
KalVista jumps 36% in a week after the FDA clears Ekterly, the first oral on-demand therapy for hereditary angioedema.
